Código 300439 (Harmonized System 2012 by 6 digits)
2023: US$653M, Total Trade Exchange
2023: US$69M, International Sales
2023: US$585M, International Purchases
In 2023, the trade exchange (includes international purchases and sales) of Medicaments Containing Hormones or Steroids Used as Hormones but not Antibiotics, in Measured Doses was US$653M.
In 2023, the states with the most international sales in Medicaments Containing Hormones or Steroids Used as Hormones but not Antibiotics, in Measured Doses were Estado de México (US$35.6M), Ciudad de México (US$16.2M), Jalisco (US$13.8M), Yucatán (US$1.58M), and Querétaro (US$744k).
The states with the most international purchases in 2023 were Ciudad de México (US$497M), Estado de México (US$69M), Jalisco (US$9.96M), and Querétaro (US$184k).
In 2023, the main commercial destinations of Medicaments Containing Hormones or Steroids Used as Hormones but not Antibiotics, in Measured Doses were Colombia (US$15.1M), Germany (US$9.52M), Panama (US$8.52M), Ecuador (US$5.46M), and United States (US$5.33M).
The main commercial origins of Medicaments Containing Hormones or Steroids Used as Hormones but not Antibiotics, in Measured Doses in 2023 were United States (US$158M), Denmark (US$112M), Germany (US$70.1M), France (US$43.5M), and Italy (US$32.6M).
In the global context, the main exporting countries of Medicaments Containing Hormones or Steroids Used as Hormones but not Antibiotics, in Measured Doses in 2022 were Denmark (US$8.72B), Italy (US$4.45B), and Germany (US$3.99B). In the same year, the main importing countries of Medicaments Containing Hormones or Steroids Used as Hormones but not Antibiotics, in Measured Doses were United States (US$11.7B), Switzerland (US$3.72B), and Italy (US$2.48B).
US$653M, Total Trade Exchange (2023)
In 2023, the total trade exchange of Medicaments Containing Hormones or Steroids Used as Hormones but not Antibiotics, in Measured Doses in Mexico (including international purchases and sales) was US$653M.
The visualizations show the net balance of Medicaments Containing Hormones or Steroids Used as Hormones but not Antibiotics, in Measured Doses at the level of states and countries. Colors more similar to blue, indicate that the territory presented a higher level of international sales. Colors more similar to red, indicate that the territory presented a higher level of international purchases.
November, 2024
In November 2024, international sales of Medicaments Containing Hormones or Steroids Used as Hormones but not Antibiotics, in Measured Doses were US$21.5M, while international purchases reached US$51M. The above results in a trade balance of -US$29.5M.
2024-Q4: US$3.65M, International Sales
The visualization shows the quarterly concentration of international sales of Medicaments Containing Hormones or Steroids Used as Hormones but not Antibiotics, in Measured Doses at state level.
In the fourth quarter of 2024, international sales were US$3.65M, being the states with the most sales Jalisco (US$2.09M), Ciudad de México (US$1.56M), and Querétaro (US$2.1k).
Estado de México: US$35.6M, State with the Most International Sales (2023)
Colombia: US$15.1M, Main commercial destination (2023)
In 2023, the states with the highest international sales in Medicaments Containing Hormones or Steroids Used as Hormones but not Antibiotics, in Measured Doses were Estado de México (US$35.6M), Ciudad de México (US$16.2M), Jalisco (US$13.8M), Yucatán (US$1.58M), and Querétaro (US$744k).
In 2023, the countries with the most international purchases from Mexico were Colombia (US$15.1M), Germany (US$9.52M), Panama (US$8.52M), Ecuador (US$5.46M), and United States (US$5.33M).
Ciudad de México: US$497M, State with the Most International Purchases (2023)
United States: US$158M, Main Commercial Origin (2023)
In 2023, the states with the highest international in Medicaments Containing Hormones or Steroids Used as Hormones but not Antibiotics, in Measured Doses were Ciudad de México (US$497M), Estado de México (US$69M), Jalisco (US$9.96M), and Querétaro (US$184k).
The countries with the most international sales to Mexico in 2023 were United States (US$158M), Denmark (US$112M), Germany (US$70.1M), France (US$43.5M), and Italy (US$32.6M).
The RCA-Complexity diagram compares the Revelead Comparative Advantages of states in Medicaments Containing Hormones or Steroids Used as Hormones but not Antibiotics, in Measured Doses and the Economic Complexity Index of each state.
RCA values greater than 1 indicate that the state has comparative advantages in Medicaments Containing Hormones or Steroids Used as Hormones but not Antibiotics, in Measured Doses. On the other hand, high levels of complexity (ECI) are associated with higher levels of income, potential for economic growth, lower income inequality and lower emissions.
The visualizations show the global market for Medicaments Containing Hormones or Steroids Used as Hormones but not Antibiotics, in Measured Doses. In both charts, Mexico stands out in order to identify its participation in the export and import market.
In 2022, the main exporting countries of Medicaments Containing Hormones or Steroids Used as Hormones but not Antibiotics, in Measured Doses were Denmark (US$8.72B), Italy (US$4.45B), and Germany (US$3.99B). In the same year, the main importing countries for Medicaments Containing Hormones or Steroids Used as Hormones but not Antibiotics, in Measured Doses were United States (US$11.7B), Switzerland (US$3.72B), and Italy (US$2.48B).